Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dupilumab: One therapy to treat multiple atopic diseases

JAAD Case Reports(2020)10.1016/j.jdcr.2020.08.036Source: DataRank Database

Dupilumab: One therapy to treat multiple atopic diseases is a research paper published in JAAD Case Reports (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.79)OA: goldTopics (36)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Abigail I. Franco ORCID,Lisa A. Beck ORCID,Fatima Bawany ORCID

Live enrichment

PubMed:33134458 PMC:PMC7591322 OpenAlex:https://openalex.org/W3084018587

National Institute of Allergy and Infectious Diseases

Grant: U19AI117673

NCATS NIH HHS

Grant: TL1 TR002000

National Institutes of Health

Grant: 5TL1TR002000-07

NRSA Training Core

National Institutes of Health

Grant: 1U19AI117673-01

Control of Microbiome Function by the Barrier in Atopic Dermatitis

National Center for Advancing Translational Sciences

National Institutes of Health

FWCI

0.79

Citation Percentile

0.7%

Citation Trend

2022

2024

2025

goldLicense: cc-by

journalhttp://www.jaadcasereports.org/article/S2352512620306470/pdf

publisherhttp://www.jaadcasereports.org/article/S2352512620306470/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2352512620306470?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352512620306470?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jdcr.2020.08.036

Fields of Study

Asthma and respiratory diseasesEosinophilic EsophagitisDermatology and Skin Diseases03 medical and health sciences0302 clinical medicine

Keywords

DupilumabMedicineEosinophilic esophagitisAtopic dermatitisAsthmaOmalizumabImmunologyAllergyFood allergyInterleukin 13BenralizumabDermatologyInterleukinMepolizumabImmunoglobulin EEosinophilCytokineAntibodyDiseaseInternal medicineallergic rhinitisChronic SinusitisIl, InterleukinAd, Atopic DermatitisEgd, EsophagogastroduodenoscopyAr, Allergic RhinitisCrwnp, Chronic Rhinosinusitis With Nasal PolyposisCs, Chronic SinusitisEoe, Eosinophilic EsophagitisRL1-803Case Report

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Dupilumab: One therapy to treat multiple atopic diseases

FAIR Checklist

Authors (3)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)